NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
17y agoen
From the article
NICE issued appraisal against NHS funding for Tyverb, treatment for breast cancer (ErbB2-positive).1.
Continue reading on GSKYou might also wanna read
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
clinicaltrials.gov·8d ago
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
clinicaltrials.gov·3d ago
New cancer drug trial offers hope for patients with rare aggressive tumour
Reading Chronicle·1d ago
Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC
clinicaltrials.gov·3d ago
CRIS Contra el Cáncer financia una nueva estrategia de terapias dirigidas frente al cáncer de ovario
Infobae·2d ago
The immunology of human breast cancer
doi.org·18d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.